<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In vitro studies of the canine basilar artery have demonstrated that calmodulin antagonism can effectively inhibit cerebral arterial smooth muscle contractility </plain></SENT>
<SENT sid="1" pm="."><plain>The prophylactic and therapeutic effectiveness of a potent calmodulin <z:chebi fb="68" ids="48706">antagonist</z:chebi>, the <z:chebi fb="1" ids="37931,37932">phenothiazine</z:chebi> compound <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> (TFP), was investigated in vivo over a wide range of doses in the well-documented "double-<z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo>" canine model of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The compound is perhaps more well-known under its trade name, Stelazine, as a classic <z:chebi fb="0" ids="35476">antipsychotic drug</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The drug demonstrated no therapeutic relief of preexisting <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> at any time during 2 days of systemic administration at any practical dose </plain></SENT>
<SENT sid="4" pm="."><plain>At doses far in excess of the normally accepted therapeutic range in humans, a prophylactic regimen reduced the severity of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> by approximately 35% compared to untreated dogs </plain></SENT>
</text></document>